The higher succession rate of hematopoietic stem cell transplantation (HSCT) and other major driving factors is expected to favour the rise in the global hematopoietic stem cell transplantation (HSCT) market
Reports and Insights has published a new report titled, “Hematopoietic Stem Cell Transplantation (HSCT) Market: Opportunity Analysis and Future Assessment 2020-2028”
Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type (Allogeneic, Autologous), By Indication (Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Hodgkin lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Other Non-Malignant Disorders), By Application (Bone Marrow Transplant (BMT), Peripheral Blood Stem Cells Transplant (PBSCT), Cord Blood Transplant (CBT)) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2020 and 2028.
The global hematopoietic stem cell transplantation (HSCT) market in 2020 is estimated for more than US$ xx Bn and expected to reach a value of US$ xx Bn by 2028 with a significant CAGR of xx%.
Hematopoietic stem cell transplantation (HSCT) can be understood as a treatment approach that serve its utility to destroy disease activity by initially expunging the immune system with the help of cytotoxic drugs (chemotherapy) succeeded by the preface of autologous hematopoietic (blood-derived) stem cells to assist in restoration of the lost immune system.
The rapidly growing prevalence of leukemia and lymphoma among the population all around the world is majorly boosting the demand of hematopoietic stem cell transplantation (HSCT) all across the global markets. According to the reports of Leukemia & Lymphoma Society, an approximate 1,519,907 people in the United States (US) are coexisting with leukemia, myeloma, lymphoma, myeloproliferative neoplasms (MPNs) or myelodysplastic syndromes (MDS).
Moreover, the succession rates of hematopoietic stem cell transplantation (HSCT) is higher than ever which further gains patients’ compliance worldwide which further acts as a positive factor for the significant growth of the market in the following years.
However, factors like higher cost of transplantation and inadequacy of funding for organizations such as the Worldwide Network for Blood & Marrow Transplantation (WBMT) are estimated to slow down the global hematopoietic stem cell transplantation market over the years.
Nonetheless, the growing aging population all across is world is further adding to the rising incidence of hematopoietic disorders, ultimately propelling the demand of hematopoietic stem cell transplantation (HSCT) across the markets. Therefore, the global hematopoietic stem cell transplantation (HSCT) market is projected to witness significant growth in the coming years.
Reports and Insights Study identifies some of the key participating players in the hematopoietic stem cell transplantation (HSCT) market globally are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics, Inc., Marker Therapeutics Inc., and Stempeutics Research Pvt Ltd., among others.
About Reports and Insights
Reports and Insights is one of the leading market research companies which offers syndicate and consulting research around the globe. At Reports and Insights we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with a strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.
Reports and Insights
For Sales Query: [email protected]
For New Topics & Other Info: [email protected]